中文摘要：

目的探讨耐亚胺培南鲍曼不动杆菌（IRAB）的临床分布及其耐药性,为临床治疗该菌感染提供依据。方法回顾性分析我院2009～2011年分离的165株IRAB的临床分布及其耐药情况。结果①鲍曼不动杆菌中IRAB的检出率为42.2%（165/391）;IRAB主要分布于重症监护病房（ICU）,占67.3%（111/165）;主要来源于呼吸道标本,占64.8%（107/165）。②IRAB对13种抗菌药物的耐药率：哌拉西林、替卡西林/克拉维酸、头孢噻肟、头孢曲松、复方新诺明、环丙沙星、庆大霉素、头孢他啶、左氧氟沙星、妥布霉素均大于70%,阿米卡星68.7%,氨苄西林/舒巴坦61.8%头孢哌酮/舒巴坦20.3%;泛耐药率9.2%（36/391）。结论 IRAB耐药性严重,表现为多重耐药以至泛耐药,临床应根据药敏结果选用抗菌药物,头孢哌酮/舒巴坦为首选经验用药。

英文摘要：

Objective To discussion of imipenem-resistant Acinetobacter Bauman （IRAB） clinical distribution and drug resistance for the clinical treatment of the bacterial infection. Methods Aretrespective analysis of our hospital 165 clinical isolates of IRAB distribution and drug resistance from 2009 to 2011. Results ① IRAB detection rate was 42.2% （ 165/391 ）, mainly distributed in the intensive care unit （ ICU）, accounted for 67.3% （ 111/165 ）, mainly from respiratory tract specimens, accounted for 64. 8% （ 107/165 ）. ② 14 antibacterial drug resistance rate ： Piperacillin, Ticarcillin/Clavulanate, Ccftriaxone, Cefotaxime, Cotrimoxazole, Ciprofloxacin, Gentamicin, Ceftazidime, Levofloxacin, Tobramycin are more than 70%, Amikacin 68.7 %, Ampi- cillin / Sulbactam 61.8%, Cefoperazone / Sulbactam20.3% ;the pandrug resistance rate of 9. 2% （36/391）. Conclusion IRAB resistance in severe,performance for multiple resistance even pandrug-resistant, application of antibacterial drug according to the results of drug sensitivity, Cefoperazone / Sulbactam is the preferred experience.